Tricyclic cefem sulphones
    22.
    发明授权
    Tricyclic cefem sulphones 失效
    三环头孢磺酸钠

    公开(公告)号:US5585372A

    公开(公告)日:1996-12-17

    申请号:US367319

    申请日:1995-01-20

    CPC分类号: C07D501/00

    摘要: The present invention provides compounds of formula (I) and pharmaceutically or veterinarily salts thereof; ##STR1## wherein R.sub.1 is hydrogen or halogen or an organic group; R.sub.2 is hydrogen or an optionally substituted C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.6 -C.sub.10 aryl or C.sub.7 -C.sub.14 aralkyl group;R.sub.3 is hydrogen or halogen, or an organic groupR.sub.4 is hydrogen or a group defined as R.sub.2 above or R.sub.4 taken together with R.sub.3 constitutes a C.sub.2 -C.sub.6 alkanediyl or an alkanediyl radical optionally substituted by methyl or phenyland X is either oxygen or sulphur or NR.sub.6, wherein R.sub.6 is either hydrogen or a group as defined for R.sub.2. A process for their preparation by cyclization of appropriate intermediates is also described.The compounds of formula I and the pharmaceutically and veterinarily acceptable salts thereof are elastase inhibitors.

    摘要翻译: PCT No.PCT / EP94 / 01643 Sec。 371 1995年1月20日第 102(e)1995年1月20日PCT PCT 1994年5月17日PCT公布。 WO94 / 28003 PCT出版物 日期:1994年12月8日本发明提供式(I)化合物及其药学上或兽用盐; (I)其中R1是氢或卤素或有机基团; R 2是氢或任选取代的C 1 -C 6烷基,C 3 -C 6环烷基,C 6 -C 10芳基或C 7 -C 14芳烷基; R3是氢或卤素,或有机基团R4是氢或被定义为R2上面的R2或与R4一起构成的基团构成任选被甲基或苯基取代的C 2 -C 6烷二基或烷二基,X是氧或硫或 NR 6,其中R 6是氢或根据R 2定义的基团。 还描述了通过合适的中间体的环化制备其方法。 式I化合物及其药学上和兽医学上可接受的盐是弹性蛋白酶抑制剂。

    2,2-disubstituted cephem sulphones
    23.
    发明授权
    2,2-disubstituted cephem sulphones 失效
    2,2-二取代的头孢烯砜

    公开(公告)号:US5580865A

    公开(公告)日:1996-12-03

    申请号:US43023

    申请日:1993-04-05

    CPC分类号: C07D501/00

    摘要: The present invention provides cephalosporin sulphones or formula (I), and pharmaceutically or veterinarily acceptable salts thereof; ##STR1## wherein n is zero, one or two; R.sub.1 is hydrogen, halogen or an optionally substituted C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio or C.sub.1 -C.sub.4 carboxamido group;R.sub.2 is hydrogen or an optionally substituted C.sub.1 -C.sub.8 alkyl, C.sub.6 -C.sub.10 aryl, C.sub.2 -C.sub.5 alkenyl or C.sub.3 -C.sub.6 cycloalkyl group;R.sub.3 is hydrogen or acetoxymethyl, methoxymethyl, methyl or an optionally substituted heterocyclylthiomethyl group;R.sub.4 is an optionally substituted C.sub.1 -C.sub.8 alkyl, C.sub.2 -C.sub.6 alkenyl, aryl(C.sub.1 -C.sub.8)alkyl or heterocyclyl(C.sub.1 -C.sub.8)alkyl group; andR.sub.5 is an optionally substituted C.sub.6 -C.sub.10 aryl or a heterocyclyl group.The compounds of formula I and the pharmaceutically and veterinarily acceptable salts thereof are elastase inhibitors.

    摘要翻译: 本发明提供头孢菌素砜或式(I)化合物及其药学或兽医学上可接受的盐; (I)其中n为0,1或2; R 1是氢,卤素或任选取代的C 1 -C 4烷基,C 2 -C 4烯基,C 1 -C 4烷氧基,C 1 -C 4烷硫基或C 1 -C 4甲酰氨基; R 2是氢或任选取代的C 1 -C 8烷基,C 6 -C 10芳基,C 2 -C 5烯基或C 3 -C 6环烷基; R3是氢或乙酰氧基甲基,甲氧基甲基,甲基或任意取代的杂环硫基甲基; R4是任选取代的C 1 -C 8烷基,C 2 -C 6烯基,芳基(C 1 -C 8)烷基或杂环基(C 1 -C 8)烷基; 并且R 5是任选取代的C 6 -C 10芳基或杂环基。 式I化合物及其药学上和兽医学上可接受的盐是弹性蛋白酶抑制剂。

    Penem derivatives
    24.
    发明授权
    Penem derivatives 失效
    Penem衍生物

    公开(公告)号:US5480880A

    公开(公告)日:1996-01-02

    申请号:US972444

    申请日:1993-04-09

    CPC分类号: C07D499/88

    摘要: The invention provides compounds of the general formula I ##STR1## wherein R.sub.1 is a hydrogen atom, a negative charge or an ester residue; R is:a) --(CH.sub.2).sub.n --A--CO.sub.2 H, --(CH.sub.2)n--A--SO.sub.3 H or --(CH.sub.2).sub.n --A--PO.sub.3 H.sub.2, wherein n is either zero, one or two and A is a group --CH.dbd.CH-- (either E or Z), --OCH.sub.2 --, --SCH.sub.2 -- or --CHOH--;b) --(CH.sub.2).sub.n --PO.sub.3 H.sub.2, --(CH.sub.2).sub.n SO.sub.2 NHCN, --(CH.sub.2).sub.n NHSO.sub.3 H, --(CH.sub.2).sub.n CONHSO.sub.2 CH.sub.3 or --(CH.sub.2).sub.n CONHSO.sub.2 CF.sub.3, wherein n is as defined above;c) --(CH.sub.2 S).sub.m --W--(CH.sub.2).sub.n Z, wherein W is an arylene group or a heterocyclediyl group, m is 0 or 1, n is as above defined, and Z represents CO.sub.2 H, PO.sub.3 H.sub.2, SO.sub.2 NHCN, NHSO.sub.3 H, CONHSO.sub.2 CH.sub.3 or CONHSO.sub.2 CF.sub.3 ;d) ##STR2## wherein Y is O or NH and X is NH, N--OH or N--O--(CH.sub.2).sub.n+1 COOH wherein n is as defined above; ore) --(CH.sub.2 S).sub.m --W', wherein W' is a heterocyclyl group convertible into an anion at physiological pH and m is as defined above.Compounds I, their salts and ester prodrugs have antibacterial activity.

    摘要翻译: PCT No.PCT / EP92 / 01396 Sec。 371日期:1993年4月9日 102(e)日期1993年4月9日PCT提交1992年6月22日PCT公布。 出版物WO93 / 00345 日本1993年1月7日。本发明提供通式Ⅰ(I)的化合物,其中R1是氢原子,负电荷或酯残基; R是:a) - (CH 2)n A-CO 2 H, - (CH 2)n A-SO 3 H或 - (CH 2)n A-PO 3 H 2,其中n是零,一个或两个,A是基团-CH = CH- E或Z),-OCH 2 - , - CH 2 - 或-CHOH-; b) - (CH 2)n -PO 3 H 2, - (CH 2)n SO 2 NHCN, - (CH 2)n NHSO 3 H, - (CH 2)n CONHSO 2 CH 3或 - (CH 2)n CONHSO 2 CF 3,其中n如上所定义; c) - (CH 2 S)m W-(CH 2)n Z,其中W是亚芳基或杂环基,m是0或1,n如上所定义,Z代表CO 2 H,PO 3 H 2,SO 2 NHCN,NHSO 3 H,CONHSO 2 CH 3或CONHSO 2 CF 3 ; d)其中Y是O或NH,X是NH,N-OH或N-O-(CH 2)n + 1COOH,其中n如上定义; 或e) - (CH 2 S)m -W',其中W'是在生理pH下可转化成阴离子的杂环基,m如上所定义。 化合物I,其盐和酯前药具有抗菌活性。

    Process for the preparation of 7 alpha-alkoxycephem derivatives
    25.
    发明授权
    Process for the preparation of 7 alpha-alkoxycephem derivatives 失效
    制备7α-烷氧基头孢烯衍生物的方法

    公开(公告)号:US5254680A

    公开(公告)日:1993-10-19

    申请号:US691089

    申请日:1991-04-25

    CPC分类号: C07D501/00

    摘要: There is provided a process for preparing a compound of the formula (I): ##STR1## wherein R.sub.1 is an organic residue, R.sub.2 is a hydrogen or a chlorine atom, a methoxy, ethoxy or an acetoxy group, and n represents 0, 1 or 2.The process comprises reacting a compound of the formula (II): ##STR2## wherein R.sub.2 and n are as defined above, with an inorganic or organic nitrite, in an alcohol R.sub.1 OH, wherein R.sub.1 is as defined above, or in a mixture R.sub.1 OH-organic solvent in the presence of an inorganic or organic acid.The compounds of the formula (I) are known intermediates in the synthesis of human leucocyte elastase inhibitors (HLE).

    摘要翻译: 提供了制备式(I)化合物的方法:其中R1是有机残基,R2是氢或氯原子,甲氧基,乙氧基或乙酰氧基,n表示 该方法包括使式(II)化合物:其中R2和n如上所定义的化合物与无机或有机亚硝酸盐在醇R 1 OH中反应,其中R 1为 或在无机或有机酸存在下,在混合物中的R1OH-有机溶剂中。 式(I)的化合物是合成人类白细胞弹性蛋白酶抑制剂(HLE)的已知中间体。

    Matrix metalloproteinase inhibitors
    30.
    发明授权
    Matrix metalloproteinase inhibitors 失效
    基质金属蛋白酶抑制剂

    公开(公告)号:US06482827B1

    公开(公告)日:2002-11-19

    申请号:US09147798

    申请日:1999-03-10

    IPC分类号: A61K3116

    摘要: A compound, which is an amine derivative of formula (I) wherein W is —CNHOH or —COOH: R1 and R2 are each hydrogen or an organic residue, R3 is an organic group, Q is a secondary or tertiary acyclic or cyclic amido group, and the pharmaceutically acceptable salts, solvates and hydrates thereof, are inhibitors of matrix metalloproteinases (MMPs) and of the release of tumor necrosis factor-alpha (TNF) from cells. They are therefore useful in the prevention, control and treatment of diseases in which MMPs or TNF are involved, especially tumoral and inflammatory diseases. Processes for their preparation and pharmaceutical compositions containing them are also described.

    摘要翻译: 作为式(I)的胺衍生物的化合物,其中W为-CNHOH或-COOH:R 1和R 2各自为氢或有机残基,R 3为有机基团,Q为仲或叔无环或环状酰氨基 及其药学上可接受的盐,溶剂化物和水合物,是基质金属蛋白酶(MMPs)的抑制剂和从细胞释放肿瘤坏死因子-α(TNF)的抑制剂。 因此,它们可用于预防,控制和治疗涉及MMP或TNF的疾病,特别是肿瘤和炎性疾病。 还描述了其制备方法和含有它们的药物组合物。